dc.contributor.author | Tastekin, Didem | |
dc.contributor.author | Sakar, Burak | |
dc.contributor.author | Karabulut, Senem | |
dc.contributor.author | Ferhatoglu, Ferhat | |
dc.contributor.author | Paksoy, Nail | |
dc.contributor.author | DOĞAN, İzzet | |
dc.date.accessioned | 2023-02-21T07:58:08Z | |
dc.date.available | 2023-02-21T07:58:08Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | DOĞAN İ., Karabulut S., Tastekin D., Ferhatoglu F., Paksoy N., Sakar B., "Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer", JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, cilt.32, sa.8, ss.1014-1019, 2022 | |
dc.identifier.issn | 1022-386X | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_11ad75d6-f431-478c-9310-79b8ce847691 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/186264 | |
dc.identifier.uri | https://doi.org/10.29271/jcpsp.2022.08.1014 | |
dc.identifier.uri | https://avesis.istanbul.edu.tr/api/publication/11ad75d6-f431-478c-9310-79b8ce847691/file | |
dc.description.abstract | Objective: To determine the efficacy of trastuzumab-based treatment in patients with HER2/neu-positive metastatic gastric cancer. Study Design: Observational study. Place and Duration of Study: Department of Medical Oncology, Istanbul University, Institute of Oncology, Istanbul, Turkey, between January 2014 and December 2020. Methodology: The clinicopathological characteristic and treatment data of patients with HER2/neu-positive metastatic gastric cancer were recorded retrospectively. Kaplan-Meier analysis was performed to compare the chemotherapy regimens. Results: Sixty-three patients were included in the study. The average age was 61. Female patients accounted for 27% of the total, while male patients accounted for 73%. De novo metastatic cases accounted for 44 (69.8%) of the total number of patients. The median survival time was 13.6 (8-19.3) months. Complete response was 6.3%, partial response was 39.7%, and the stable response was 9.5% with trastuzumab-based chemotherapy. The overall survival (p= 0.45) and progression-free survival (p=0.893) were similar for different chemotherapy regimens. The grade 1-2 to grade 3-4 toxicity ratio was 79.6% and 20.6%, respectively. The patients' performance (p<0.001) and the number of metastatic sites (p=0.001) were both shown to be unfavourable predictive variables for OS in multivariate analysis. Conclusion: The addition of taxane to trastuzumab-based combinations (with platinum and fluoropyrimidine) did not affect overall and progression-free survival in this research. Three or more metastatic sites and poor performance status were found as the unfavourable prognostic variables for overall survival. | |
dc.language.iso | eng | |
dc.subject | Değerlendirme ve Teşhis | |
dc.subject | Dahiliye | |
dc.subject | Aile Sağlığı | |
dc.subject | Tıp (çeşitli) | |
dc.subject | Genel Tıp | |
dc.subject | Genel Sağlık Meslekleri | |
dc.subject | Patofizyoloji | |
dc.subject | Temel Bilgi ve Beceriler | |
dc.subject | Temel Tıp Bilimleri | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | TIP, GENEL & DAHİLİ | |
dc.title | Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer | |
dc.type | Makale | |
dc.relation.journal | JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 32 | |
dc.identifier.issue | 8 | |
dc.identifier.startpage | 1014 | |
dc.identifier.endpage | 1019 | |
dc.contributor.firstauthorID | 3450253 | |